Advertisement

American Journal of Cardiovascular Drugs

, Volume 19, Issue 6, pp 597–605 | Cite as

Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure

  • Kenji Yoshioka
  • Yuya MatsueEmail author
  • Tetsuo Yamaguchi
  • Takeshi Kitai
  • Nobuyuki Kagiyama
  • Takahiro Okumura
  • Keisuke Kida
  • Shogo Oishi
  • Eiichi Akiyama
  • Satoshi Suzuki
  • Masayoshi Yamamoto
  • Shunsuke Kuroda
  • Akihiko Matsumura
  • Kenzo Hirao
Original Research Article

Abstract

Background

Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been recommended for patients with heart failure, their clinical and prognostic impact in the very acute phase of acute heart failure (AHF) is unclear, mainly because data on their safety and efficacy are lacking.

Methods

This study was a post hoc analysis of the REALITY-AHF trial. Patients with AHF who did not take an ACEI or ARB at admission were enrolled. Patients who received these medications within 48 h of admission were categorized as the ACEI/ARB group, and all other patients were categorized as the no ACEI/ARB group. The primary endpoint was a composite of all-cause death and heart failure readmission within 1 year of admission.

Results

Of the 1682 patients in the REALITY-AHF cohort, 900 were enrolled in this study, and 288 (32%) were included in the ACEI/ARB group. After propensity score matching, 152 pairs were evaluated, and no significant difference was found for in-hospital mortality, worsening renal function, or length of hospital stay. The ACEI/ARB group had significantly higher event-free survival (hazard ratio 0.51; 95% confidence interval 0.32–0.82; p = 0.006).

Conclusions

Early initiation of ACEIs/ARBs within 48 h of admission for hospitalized patients with AHF was not associated with adverse events and correlated with improved outcomes at 1 year from admission.

Notes

Compliance with Ethical Standards

Funding

This study was partly supported by a Grant-in-Aid for Early-Career Scientists (Grant no. 18K15862) and The Cardiovascular Research Fund, Tokyo, Japan.

Conflict of interest

Dr. Yuya Matsue has received an honorarium and grants from Otsuka Pharmaceutical Co. Kenji Yoshioka, Tetsuo Yamaguchi, Takeshi Kitai, Nobuyuki Kagiyama, Takahiro Okumura, Keisuke Kida, Shogo Oishi, Eiichi Akiyama, Satoshi Suzuki, Masayoshi Yamamoto, Shunsuke Kuroda, Akihiko Matsumura, and Kenzo Hirao have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Supplementary material

40256_2019_355_MOESM1_ESM.pdf (345 kb)
Supplementary material 1 (PDF 345 kb)

References

  1. 1.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRefGoogle Scholar
  2. 2.
    SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefGoogle Scholar
  3. 3.
    Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–77.CrossRefGoogle Scholar
  4. 4.
    Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989;13:134–42.CrossRefGoogle Scholar
  5. 5.
    Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation. 1996;94:1316–24.CrossRefGoogle Scholar
  6. 6.
    Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J. 1994;15(Suppl B):14–9 (discussion 26–30).CrossRefGoogle Scholar
  7. 7.
    Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen ZM, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting. J Am Coll Cardiol. 2000;35:1801–7.CrossRefGoogle Scholar
  8. 8.
    Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042–51.CrossRefGoogle Scholar
  9. 9.
    Kondo T, Okumura T, Matsue Y, Shiraishi A, Kagiyama N, Yamaguchi T, et al. Specialty-related differences in the acute-phase treatment and prognosis in patients with acute heart failure—insights from REALITY-AHF. Circ J. 2018;83:174–81.CrossRefGoogle Scholar
  10. 10.
    Kuroda S, Damman K, Ter Maaten JM, Voors AA, Okumura T, Kida K, et al. Very early diuretic response after admission for acute heart failure. J Card Fail. 2019;25:12–9.CrossRefGoogle Scholar
  11. 11.
    Yamaguchi T, Kitai T, Miyamoto T, Kagiyama N, Okumura T, Kida K, et al. Effect of optimizing guideline-directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction. Am J Cardiol. 2018;121:969–74.CrossRefGoogle Scholar
  12. 12.
    Kagiyama N, Kitai T, Hayashida A, Yamaguchi T, Okumura T, Kida K, et al. Prognostic value of BNP reduction during hospitalization in patients with acute heart failure. J Card Fail. 2019;1:1.  https://doi.org/10.1016/j.cardfail.2019.04.004.CrossRefGoogle Scholar
  13. 13.
    Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–15.CrossRefGoogle Scholar
  14. 14.
    Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials. Circulation. 2015;132:302–61.CrossRefGoogle Scholar
  15. 15.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefGoogle Scholar
  16. 16.
    Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188–95.CrossRefGoogle Scholar
  17. 17.
    Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–61.CrossRefGoogle Scholar
  18. 18.
    Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314:1637.CrossRefGoogle Scholar
  19. 19.
    SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.CrossRefGoogle Scholar
  20. 20.
    Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724–31.CrossRefGoogle Scholar
  21. 21.
    Sanam K, Bhatia V, Bajaj NS, Gaba S, Morgan CJ, Fonarow GC, et al. Renin-angiotensin system inhibition and lower 30-day all-cause readmission in medicare beneficiaries with heart failure. Am J Med. 2016;129:1067–73.CrossRefGoogle Scholar
  22. 22.
    WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.Google Scholar
  23. 23.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18:891–975.CrossRefGoogle Scholar
  24. 24.
    Cleland JG, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985;54:305–12.CrossRefGoogle Scholar
  25. 25.
    Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, et al. Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J. 2013;77:687–96.CrossRefGoogle Scholar
  26. 26.
    Yuan BH, Robinette JB, Conger JD. Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol Physiol. 1990;258:F741–50.CrossRefGoogle Scholar
  27. 27.
    Schroten NF, Damman K, Hemmelder MH, Voors AA, Navis G, Gaillard CAJM, et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Am Heart J. 2015;169(693–701):e3.Google Scholar
  28. 28.
    Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail. 2011;13:961–7.CrossRefGoogle Scholar
  29. 29.
    Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, et al. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? Eur J Heart Fail. 2018;20:317–22.CrossRefGoogle Scholar
  30. 30.
    Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JI. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed). 1983;286:832–4.CrossRefGoogle Scholar
  31. 31.
    Panzenbeck MJ, Loughnan CL, Madwed JB, Winquist RJ, Fogal SE. Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na(+)-depleted marmosets. Am J Physiol. 1995;269:H1221–8.PubMedGoogle Scholar
  32. 32.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.CrossRefGoogle Scholar
  33. 33.
    Zhang Q, Chen Y, Liu Q, Shan Q. Effects of renin–angiotensin–aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. Herz. 2016;41:76–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kenji Yoshioka
    • 1
    • 2
  • Yuya Matsue
    • 3
    • 4
    Email author
  • Tetsuo Yamaguchi
    • 5
  • Takeshi Kitai
    • 6
  • Nobuyuki Kagiyama
    • 7
  • Takahiro Okumura
    • 8
  • Keisuke Kida
    • 9
  • Shogo Oishi
    • 10
  • Eiichi Akiyama
    • 11
  • Satoshi Suzuki
    • 12
  • Masayoshi Yamamoto
    • 13
  • Shunsuke Kuroda
    • 1
    • 2
  • Akihiko Matsumura
    • 1
  • Kenzo Hirao
    • 2
  1. 1.Department of CardiologyKameda Medical CenterChibaJapan
  2. 2.Department of Cardiovascular MedicineTokyo Medical and Dental UniversityTokyoJapan
  3. 3.Department of Cardiovascular MedicineJuntendo UniversityTokyoJapan
  4. 4.Cardiovascular Respiratory Sleep MedicineJuntendo University Graduate School of MedicineTokyoJapan
  5. 5.Department of CardiologyJapanese Red Cross Musashino HospitalTokyoJapan
  6. 6.Department of Cardiovascular MedicineKobe City Medical Center General HospitalKobeJapan
  7. 7.Department of CardiologyThe Sakakibara Heart Institute of OkayamaOkayamaJapan
  8. 8.Department of CardiologyNagoya University School of MedicineNagoyaJapan
  9. 9.Department of PharmacologySt. Marianna University School of MedicineKawasakiJapan
  10. 10.Department of CardiologyHimeji Cardiovascular CenterHimejiJapan
  11. 11.Division of CardiologyYokohama City University Medical CenterYokohamaJapan
  12. 12.Department of Cardiovascular MedicineFukushima Medical UniversityFukushimaJapan
  13. 13.Cardiovascular Division, Faculty of MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations